Wall Street Analysts Raise Price Target for Recursion Pharmaceuticals to $7.32
Wall Street analysts covering Recursion Pharmaceuticals, Inc. (RXRX) raised their average 12-month price target to $7.32 per share, up from a previous average of $7.22. Based on the Oct. 15 closing price, the new consensus target points to a potential upside of approximately 76%. Shares of the company recently traded at $4.16, marking an 11.23% gain for the day.
The revised price target represents predictions from six covering analysts, with individual estimates ranging from a low of $4 to a high of $10 per share. The overall consensus rating for the company stays at Buy among seven analysts total, comprising three Buy recommendations, four Hold recommendations, and zero Sell recommendations.
Going forward, market participants will watch whether the biotech firm can make progress toward the upper end of analyst expectations or if future clinical and operational updates will shift the current sentiment among covering firms.
Key points
- The average 12-month price target for Recursion Pharmaceuticals, Inc. (RXRX) rose to $7.32 from $7.22.
- The updated target implies an estimated 76% upside relative to the stock's Oct. 15 closing price.
- Analyst price targets for the share price range from a low of $4 to a high of $10.
- Seven analysts cover the stock with a consensus Buy rating, consisting of 3 Buys, 4 Holds, and 0 Sells.
- Shares of the company recently traded at $4.16, up 11.23% for the session.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the updated price target for Recursion Pharmaceuticals stock?
Six analysts set an average 12-month price target of $7.32 for Recursion Pharmaceuticals, Inc. (RXRX), up from $7.22. Individual targets range from $4 to $10 per share.
What is the consensus analyst rating for Recursion Pharmaceuticals?
The consensus rating remains Buy among seven covering analysts, with three issuing Buy ratings, four holding a Hold rating, and zero Sell ratings.
How much upside does the consensus price target imply for RXRX stock?
Based on the closing price on Oct. 15, the updated consensus price target of $7.32 suggests a potential upside of about 76%.